Role of inflammatory markers in predicting hepatocellular carcinoma recurrence after liver transplantation

被引:0
作者
Badwei, Nourhan [1 ]
Monsef, Waheed A. [1 ]
Montasser, Iman [1 ]
Bahaa, Mohamed [2 ]
El Meteini, Mahmoud [2 ]
Kamel, Shimaa Y. [1 ]
机构
[1] Ain Shams Univ, Trop Med Gastroenterol & Hepatol, Fac Med, Cairo, Egypt
[2] Ain Shams Univ, Hepatobiliary Surg, Fac Med, Cairo, Egypt
关键词
Liver transplantation; HCC recurrence; Inflammatory markers; Outcome; C-REACTIVE PROTEIN; TO-LYMPHOCYTE RATIO; VASCULAR INVASION; NEUTROPHIL; PLATELET; SURVIVAL; RISK; CANCER; SCORE; TIME;
D O I
10.1186/s43066-021-00105-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundLiver transplantation (LT) is the best treatment for selected patients with cirrhosis and small hepatocellular carcinoma (HCC) who are not candidates for resection. The proinflammatory effects of systemic inflammatory response have been linked with HCC. Therefore, the measurement of inflammatory markers represents a significant tool to limit recurrence after LT.ResultsThere are eleven patients with HCC recurrence post-transplantation. Pre-transplantation AFP can predict HCC recurrence with the best cutoff value of > 17.8 ng/ml with a sensitivity of 82% and specificity of 70%. Post-transplantation CRP can predict HCC recurrence with the best cutoff value of > 0.85 (mg/dl) with a sensitivity of 73% and specificity of 71%. Other inflammatory markers NLR and PLR were not significant in predicting HCC recurrence. Moreover, HCC recurrence significantly affects the outcome of patients undergoing LT (p value < 0.001) with a worse prognosis.ConclusionOur results showed additional benefits of inflammatory markers as CRP to standard parameters in predicting HCC recurrence to refine recipient selection and achieve better survival outcomes post-LT.
引用
收藏
页数:10
相关论文
共 39 条
[1]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[2]   Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma [J].
Berry, Kristin ;
Ioannou, George N. .
LIVER TRANSPLANTATION, 2013, 19 (06) :634-645
[3]   Platelets contribute to growth and metastasis in hepatocellular carcinoma [J].
Bihari, Chhagan ;
Rastogi, Archana ;
Shasthry, Saggere Muralikrishna ;
Bajpai, Meenu ;
Bhadoria, Ajeet Singh ;
Rajesh, S. ;
Mukund, Amar ;
Kumar, Anupam ;
Sarin, Shiv K. .
APMIS, 2016, 124 (09) :776-786
[4]   EASL Clinical Practice Guidelines: Liver transplantation [J].
Burra, Patrizia ;
Burroughs, Andrew ;
Graziadei, Ivo ;
Pirenne, Jacques ;
Valdecasas, Juan Carlos ;
Muiesan, Paolo ;
Samuel, Didier ;
Forns, Xavier ;
Burroughs, Andrew .
JOURNAL OF HEPATOLOGY, 2016, 64 (02) :433-485
[5]   Characterization of hepatocellular carcinoma recurrence after liver transplantation: Perioperative prognostic factors, patterns, and outcome [J].
Chan, Kun-Ming ;
Chou, Hong-Shiue ;
Wu, Ting-Jung ;
Lee, Chen-Fang ;
Yu, Ming-Chin ;
Lee, Wei-Chen .
ASIAN JOURNAL OF SURGERY, 2011, 34 (03) :128-134
[6]   Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation [J].
Citores, Maria J. ;
Lucena, Jose L. ;
de la Fuente, Sara ;
Cuervas-Mons, Valentin .
WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (01) :50-64
[7]   Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report [J].
Clavien, Pierre-Alain ;
Lesurtel, Mickael ;
Bossuyt, Patrick M. M. ;
Gores, Gregory J. ;
Langer, Bernard ;
Perrier, Arnaud .
LANCET ONCOLOGY, 2012, 13 (01) :E11-E22
[8]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[9]   C-reactive protein, a prognostic marker in hepatocellular carcinoma [J].
Dufour, Jean-Francois .
HEPATOLOGY, 2013, 57 (06) :2103-2105
[10]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386